Familial Hypercholesterolemia Treatment, Companies, Market Trends | Familial Hypercholesterolemia Infographic

Familial Hypercholesterolemia (FH) is a genetic and hereditary disorder that leads to an increased LDL (bad) cholesterol. The condition occurs at birth and can cause heart attacks at an early age.

Familial Hypercholesterolemia is an autosomal-dominant disorder associated with mutations in the LDL receptor gene that increases plasma low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Patients with FH are characterized by a less LDL clearance from the circulation and a rise in LDL synthesis, with changes in homozygotes being more marked than in heterozygotes, consistent with a gene dosage effect.

Familial Hypercholesterolemia Epidemiological Segmentation

The Epidemiological Segmentation of Familial Hypercholesterolemia in 7MM from 2017 to 2030 is segmented as:-

Prevalent Population of Familial Hypercholesterolemia
Diagnosed Prevalent Population of Familial Hypercholesterolemia
Mutation-specific Diagnosed Prevalence of Familial Hypercholesterolemia
Diagnosed Prevalence of Coronary Heart Disease due to Familial Hypercholesterolemia

Familial Hypercholesterolemia Epidemiology

The total diagnosed prevalent population of FH in the 7MM in 2017 was 965,405
The diagnosed prevalent population of FH in the United States in 2017 was 244,214
Familial Hypercholesterolemia affects both females and males equally

Familial Hypercholesterolemia Market

The market size of Familial Hypercholesterolemia in the 7MM in 2017 was 1,069.27 USD Million

Familial Hypercholesterolemia Market Drivers